Research statistics

Enfuvirtide research: publications and trials

What has been published on Enfuvirtide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Enfuvirtide works or is safe. For what it is and what the studies found, see the Enfuvirtide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

804

Since 1994

Publications in 2026 so far

1

Through November 15, 2026

Human clinical research

32.0%

252 of 787 classified

Registered clinical trials

40

ClinicalTrials.gov

Randomized controlled trials

51

Publications reporting an RCT in people

Systematic reviews and meta-analyses

1

Preclinical studies

33.4%

29 animal · 207 in vitro · 27 computational

Records that only mention it

301

Not counted above

Status in the library: FDA-approved. 17 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Enfuvirtide publications by year and evidence

1994, Preclinical (animal, in vitro, computational): 1 of 11995, Preclinical (animal, in vitro, computational): 1 of 21995, Other and not yet classified: 1 of 21996, Preclinical (animal, in vitro, computational): 1 of 31996, Other and not yet classified: 2 of 31997, Other and not yet classified: 1 of 11998, Human clinical research: 1 of 101998, Preclinical (animal, in vitro, computational): 4 of 101998, Other and not yet classified: 5 of 101999, Preclinical (animal, in vitro, computational): 2 of 131999, Reviews and meta-analyses: 2 of 131999, Other and not yet classified: 9 of 132000, Preclinical (animal, in vitro, computational): 8 of 122000, Other and not yet classified: 4 of 122001, Human clinical research: 1 of 202001, Preclinical (animal, in vitro, computational): 6 of 202001, Reviews and meta-analyses: 5 of 202001, Other and not yet classified: 8 of 202002, Human clinical research: 6 of 272002, Preclinical (animal, in vitro, computational): 3 of 272002, Reviews and meta-analyses: 2 of 272002, Other and not yet classified: 16 of 272003, Human clinical research: 12 of 832003, Preclinical (animal, in vitro, computational): 9 of 832003, Reviews and meta-analyses: 19 of 832003, Other and not yet classified: 43 of 832004, Human clinical research: 26 of 822004, Preclinical (animal, in vitro, computational): 14 of 822004, Reviews and meta-analyses: 27 of 822004, Other and not yet classified: 15 of 822005, Human clinical research: 18 of 732005, Preclinical (animal, in vitro, computational): 22 of 732005, Reviews and meta-analyses: 17 of 732005, Other and not yet classified: 16 of 732006, Human clinical research: 33 of 682006, Preclinical (animal, in vitro, computational): 14 of 682006, Reviews and meta-analyses: 14 of 682006, Other and not yet classified: 7 of 682007, Human clinical research: 31 of 632007, Preclinical (animal, in vitro, computational): 17 of 632007, Reviews and meta-analyses: 6 of 632007, Other and not yet classified: 9 of 632008, Human clinical research: 30 of 632008, Preclinical (animal, in vitro, computational): 24 of 632008, Reviews and meta-analyses: 9 of 632009, Human clinical research: 26 of 532009, Preclinical (animal, in vitro, computational): 16 of 532009, Reviews and meta-analyses: 6 of 532009, Other and not yet classified: 5 of 532010, Human clinical research: 19 of 352010, Preclinical (animal, in vitro, computational): 11 of 352010, Reviews and meta-analyses: 5 of 352011, Human clinical research: 16 of 372011, Preclinical (animal, in vitro, computational): 15 of 372011, Reviews and meta-analyses: 4 of 372011, Other and not yet classified: 2 of 372012, Human clinical research: 10 of 282012, Preclinical (animal, in vitro, computational): 13 of 282012, Reviews and meta-analyses: 3 of 282012, Other and not yet classified: 2 of 282013, Human clinical research: 7 of 242013, Preclinical (animal, in vitro, computational): 10 of 242013, Reviews and meta-analyses: 6 of 242013, Other and not yet classified: 1 of 242014, Human clinical research: 5 of 142014, Preclinical (animal, in vitro, computational): 6 of 142014, Reviews and meta-analyses: 2 of 142014, Other and not yet classified: 1 of 142015, Human clinical research: 3 of 142015, Preclinical (animal, in vitro, computational): 8 of 142015, Reviews and meta-analyses: 2 of 142015, Other and not yet classified: 1 of 142016, Human clinical research: 2 of 82016, Preclinical (animal, in vitro, computational): 6 of 82017, Preclinical (animal, in vitro, computational): 10 of 112017, Reviews and meta-analyses: 1 of 112018, Preclinical (animal, in vitro, computational): 5 of 72018, Reviews and meta-analyses: 2 of 72019, Human clinical research: 1 of 192019, Preclinical (animal, in vitro, computational): 17 of 192019, Reviews and meta-analyses: 1 of 192020, Human clinical research: 2 of 42020, Preclinical (animal, in vitro, computational): 2 of 42021, Preclinical (animal, in vitro, computational): 3 of 52021, Reviews and meta-analyses: 1 of 52021, Other and not yet classified: 1 of 52022, Preclinical (animal, in vitro, computational): 4 of 62022, Reviews and meta-analyses: 2 of 62023, Human clinical research: 1 of 72023, Preclinical (animal, in vitro, computational): 5 of 72023, Reviews and meta-analyses: 1 of 72024, Human clinical research: 2 of 72024, Preclinical (animal, in vitro, computational): 3 of 72024, Reviews and meta-analyses: 2 of 72025, Preclinical (animal, in vitro, computational): 2 of 32025, Reviews and meta-analyses: 1 of 32026 (to date), Preclinical (animal, in vitro, computational): 1 of 1Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified05010019942001200820152026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
199401001
199501012
199601023
199700011
1998140510
1999022913
2000080412
2001165820
20026321627
2003129194383
20042614271582
20051822171673
2006331414768
200731176963
200830249063
200926166553
201019115035
201116154237
201210133228
20137106124
2014562114
2015382114
201626008
20170101011
201805207
20191171019
202022004
202103115
202204206
202315107
202423207
202502103
2026 (to date)01001

Study types

In vitro study207
Review139
Editorial, letter or other128
Observational human study85
Case report60
Other clinical trial56
Randomized controlled trial51
Animal study29
Computational study27
Not yet classified17
Guideline or consensus4
Meta-analysis1

Research areas

From MeSH major topics. A paper can be in several areas.

Antimicrobial and infectious disease764
Immune system470
Reproductive and sexual health16
Dermatology14
Neurological and mental health11
Gastrointestinal5
Metabolic health5
Oncology3
Tissue repair3
Cardiovascular2
Cognitive health1
Musculoskeletal1

Registered clinical trials

11 of 25 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 33 · Terminated: 4 · Unknown status: 2 · Withdrawn: 1
Early phase 1: 1 · Phase not applicable: 4 · Phase 1: 3 · Phase 1 / Phase 2: 1 · Phase 2: 8 · Phase 2 / Phase 3: 1 · Phase 3: 8 · Phase 4: 14

TrialStatusPhaseStartedResults
Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple TherapyNCT02302547 · 224 enrolledCompletedPhase 32014-12—
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 IndividualsNCT01836068 · 11 enrolledCompletedEarly phase 12013-06—
Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleNCT00537394 · 517 enrolledCompletedPhase 32008-01Posted
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.NCT00615134 · 29 enrolledCompletedPhase 22008-01—
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected PatientsNCT00488059 · 29 enrolledTerminatedPhase 42007-06Posted
Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant VirusesNCT00460382 · 103 enrolledCompletedPhase 22007-05—
ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.NCT00461266WithdrawnPhase 42007-04—
Clinical Trial of CNS-targeted HAART (CIT2)NCT00624195 · 59 enrolledCompletedPhase 2, Phase 32007-03Posted
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoCNCT00440271 · 33 enrolledTerminatedPhase 32007-02Posted
Study of Valproic Acid to Treat HIV Infected AdultsNCT00312546 · 14 enrolledTerminatedPhase 12006-06—
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 InfectionNCT00337701 · 326 enrolledCompletedPhase 42006-06—
Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)NCT00302822 · 195 enrolledCompletedPhase 32006-04—
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.NCT00326963 · 142 enrolledCompletedPhase 42006-03Posted
Fuzeon Viral Decay Pilot StudyNCT00334022 · 18 enrolledCompletedPhase not applicable2006-02—
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment ExperienceNCT00487188 · 47 enrolledCompletedPhase 42005-11Posted
Metabolic Effects of Enfuvirtide in Healthy VolunteersNCT00657761 · 15 enrolledCompletedPhase 42005-09—
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.NCT00233883 · 58 enrolledCompletedPhase 42005-08—
A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 StudyNCT00128830 · 211 enrolledCompletedPhase 22005-06Posted
Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)NCT00120367 · 30 enrolledCompletedPhase 22005-04—
A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) InfectionNCT02569502 · 6 enrolledCompletedPhase 42005-04—
A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of TherapyNCT00344760 · 2 enrolledCompletedPhase 42005-01—
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) InfectionNCT02733419 · 84 enrolledCompletedPhase 32004-12—
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1NCT00100984 · 8 enrolledTerminatedPhase 42004-07—
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected PatientsNCT00089492 · 64 enrolledCompletedPhase 22004-07—
QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) InfectionNCT00232908 · 361 enrolledCompletedPhase 42004-06—
A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) InfectionNCT02582983 · 23 enrolledCompletedPhase 42004-02Posted
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive AdultsNCT00051831 · 19 enrolledCompletedPhase not applicable2003-10—
Cohort Study for Patients Using Fuzeon (Enfuvirtide)NCT00216359 · 200 enrolledUnknown statusPhase not applicable2003-05—
Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant VirusNCT00102934 · 20 enrolledUnknown statusPhase not applicable2003-03—
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)NCT00192660 · 80 enrolledCompletedPhase 42003-02—
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 InfectionNCT00050856 · 5 enrolledCompletedPhase 32002-11—
T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and AdolescentsNCT00022763 · 52 enrolledCompletedPhase 22001-08Posted
Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide ResistanceNCT00187551 · 25 enrolledCompletedPhase 42000-05—
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected AdultsNCT00002239 · 68 enrolledCompletedPhase 21999-05—
Study of a New Anti-HIV Drug, T-20, in HIV-Infected ChildrenNCT00001118 · 24 enrolledCompletedPhase 1——
A Study of T-20 in HIV-Positive AdultsNCT00002228 · 78 enrolledCompletedPhase 2——
T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV DrugsNCT00008528 · 525 enrolledCompletedPhase 3——
T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV DrugsNCT00021554 · 525 enrolledCompletedPhase 3——
Adding New Drugs for HIV Infected Patients Failing Current TherapyNCT00031044 · 50 enrolledCompletedPhase 1, Phase 2——
Study of Enfuvirtide in HIV-Positive SubjectsNCT00086710 · 26 enrolledCompletedPhase 1——

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.

    HIV clinical trials · March 1, 2006 · Meta-analysis · cited 23 times · open access

    PMID 16798623 · DOI 10.1310/2xvk-pbgl-735n-wh72 · Reviews and meta-analyses

  2. Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers.

    PloS one · May 23, 2019 · Randomized controlled trial · cited 24 times · open access

    PMID 31120908 · DOI 10.1371/journal.pone.0216712 · Human clinical research

  3. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.

    AIDS research and therapy · April 2, 2016 · Randomized controlled trial · cited 15 times · open access

    PMID 27042193 · DOI 10.1186/s12981-016-0101-3 · Human clinical research

  4. Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients.

    Journal of pharmaceutical sciences · October 7, 2014 · Randomized controlled trial · cited 10 times

    PMID 25291974 · DOI 10.1002/jps.24174 · Human clinical research

  5. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.

    The Journal of infectious diseases · June 24, 2013 · Randomized controlled trial · cited 33 times

    PMID 23801606 · DOI 10.1093/infdis/jit280 · Human clinical research

  6. Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).

    Antimicrobial agents and chemotherapy · November 19, 2012 · Randomized controlled trial · cited 19 times · open access

    PMID 23165467 · DOI 10.1128/aac.01662-12 · Human clinical research

  7. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

    The Journal of antimicrobial chemotherapy · November 14, 2012 · Randomized controlled trial · cited 14 times

    PMID 23152480 · DOI 10.1093/jac/dks455 · Human clinical research

  8. Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study.

    Journal of medical virology · November 1, 2012 · Randomized controlled trial · cited 6 times

    PMID 22997073 · DOI 10.1002/jmv.23388 · Human clinical research

  9. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

    The Journal of antimicrobial chemotherapy · June 28, 2011 · Randomized controlled trial · cited 34 times

    PMID 21712241 · DOI 10.1093/jac/dkr269 · Human clinical research

  10. The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.

    HIV medicine · January 1, 2011 · Randomized controlled trial · cited 17 times · open access

    PMID 20497250 · DOI 10.1111/j.1468-1293.2010.00845.x · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

    Antimicrobial agents and chemotherapy · June 1, 2002 · Other clinical trial · cited 1,565 times · open access

    PMID 12019106 · DOI 10.1128/aac.46.6.1896-1905.2002 · Human clinical research

  2. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

    Nature medicine · November 1, 1998 · Other clinical trial · cited 987 times

    PMID 9809555 · DOI 10.1038/3293 · Human clinical research

  3. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

    Proceedings of the National Academy of Sciences of the United States of America · October 1, 1994 · In vitro study · cited 931 times · open access

    PMID 7937889 · DOI 10.1073/pnas.91.21.9770 · In vitro studies

  4. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

    The New England journal of medicine · March 13, 2003 · Randomized controlled trial · cited 917 times · open access

    PMID 12637625 · DOI 10.1056/nejmoa035026 · Human clinical research

  5. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

    Journal of virology · September 1, 2000 · In vitro study · cited 743 times · open access

    PMID 10954535 · DOI 10.1128/jvi.74.18.8358-8367.2000 · In vitro studies

Latest publications

  1. A four-amino-acid deletion in gp41 enhances HIV-1 CRF01_AE Cluster 4 pathogenicity and fusion inhibitor resistance.

    Journal of virology · October 5, 2026 · In vitro study · cited 0 times · open access

    PMID 42831624 · DOI 10.1128/jvi.01158-26 · In vitro studies

  2. Transdermal delivery of enfuvirtide using dissolving microneedles integrated with novel insertion and removal indicator.

    Journal of controlled release : official journal of the Controlled Release Society · June 16, 2025 · Animal study · cited 9 times · open access

    PMID 40532764 · DOI 10.1016/j.jconrel.2025.113954 · Animal studies

  3. Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals.

    Journal of virology · April 10, 2025 · Review · cited 6 times · open access

    PMID 40207932 · DOI 10.1128/jvi.02289-24 · Reviews and meta-analyses

  4. Quality by Design-Guided Development of Hydrogel-Forming Microneedles for Transdermal Delivery of Enfuvirtide.

    ACS applied materials & interfaces · March 10, 2025 · Animal study · cited 23 times · open access

    PMID 40063825 · DOI 10.1021/acsami.5c00499 · Animal studies

  5. Investigating the combination of Temsavir and entry inhibitors on HIV replication: Synergistic and antagonistic effects observed against various R5-tropic envelopes.

    Virology · December 3, 2024 · In vitro study · cited 0 times · open access

    PMID 39642611 · DOI 10.1016/j.virol.2024.110341 · In vitro studies

  6. Recent report on indoles as a privileged anti-viral scaffold in drug discovery.

    European journal of medicinal chemistry · November 1, 2024 · Review · cited 40 times · open access

    PMID 39509946 · DOI 10.1016/j.ejmech.2024.117017 · Reviews and meta-analyses

  7. Enfuvirtide

    July 15, 2024 · Review · cited 0 times · open access

    PMID 30000878 · Reviews and meta-analyses

  8. Benign fibrous histiocytoma and cutaneous amyloidosis in a patient receiving enfuvirtide injections.

    JAAD case reports · May 29, 2024 · Case report · cited 2 times · open access

    PMID 39036613 · DOI 10.1016/j.jdcr.2024.04.047 · Human clinical research

  9. The Challenge of Adherence to a Complex Antiretroviral Therapy Regimen in an Individual With Multidrug-Resistant HIV.

    Topics in antiviral medicine · April 1, 2024 · Case report · cited 1 times · open access

    PMID 39141922 · Human clinical research

  10. Improving Anti-HIV activity and pharmacokinetics of enfuvirtide (T20) by modification with oligomannose.

    European journal of medicinal chemistry · March 8, 2024 · Animal study · cited 3 times · open access

    PMID 38479167 · DOI 10.1016/j.ejmech.2024.116299 · Animal studies

Browse all 804 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: DP-178; Enfuvirtida; Enfuvirtide; Fuzeon; Pentafuside

((TITLE_ABS:"DP-178" OR CHEM:"DP-178" OR TITLE_ABS:"DP178" OR CHEM:"DP178") OR (TITLE_ABS:"Enfuvirtida" OR CHEM:"Enfuvirtida") OR (TITLE_ABS:"Enfuvirtide" OR CHEM:"Enfuvirtide") OR (TITLE_ABS:"Fuzeon" OR CHEM:"Fuzeon") OR (TITLE_ABS:"Pentafuside" OR CHEM:"Pentafuside")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Enfuvirtide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/enfuvirtide